Fexapotide - Nymox

Drug Profile

Fexapotide - Nymox

Alternative Names: Fexapotide triflutate; NX-1207; REC-0482

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nymox Pharmaceutical Corporation
  • Developer Nymox Pharmaceutical Corporation; Recordati
  • Class Antineoplastics; Proteins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Preregistration Benign prostatic hyperplasia
  • Phase II Prostate cancer
  • No development reported Hepatocellular carcinoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatocellular carcinoma in USA (Parenteral, Injection)
  • 14 Sep 2017 European Member State accepts MAA for fexapotide for Benign prostatic hyperplasia for review
  • 31 May 2017 Pooled efficacy data from the phase III NX02-0017, NX02-0018, NX02-0020, NX02-0022 trials in Benign prostatic hyperplasia released by Nymox Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top